Tag: ASX: IMM
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Immutep gets green light for large-scale cancer product manufacturing for clinical trials
Immutep Limited, a clinical-stage biotechnology company specialising in LAG-3 immunotherapies for cancer and autoimmune diseases, has received regulatory authorisation for the commercial manufacturing of Eftilagimod Alpha (efti) at a scale of 2,000 litres for clinical trial use.
Featured Article
Xometry CEO Sanjeev Singh Sahni on how AI and digital networks are reshaping manufacturing supply chains
Australian manufacturers have long competed against distance. In an exclusive interview with Australian Manufacturing, Xometry CEO Sanjeev Singh Sahni discusses how AI can help manufacturers access more production capacity and simplify traditionally email-driven supply chains.
